Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2019	$ 1	$ 42,635	$ (41,507)	$ (836)	$ 293
Beginning Balance (in shares) at Dec. 31, 2019	93,942,652
Other comprehensive loss (income)				(20)	(20)
Common stock issued, net of transaction costs of $778		3,912			3,912
Common stock issued, net of transaction costs of $778 (Shares)	16,317,000
Warrants issued, net of transaction costs of $240		1,207			1,207
Agents' warrants issued		169			169
Conversion of convertible debentures		103			103
Conversion of convertible debentures (in shares)	282,000
Interest paid by issuance of common shares		234			234
Interest paid by issuance of common shares (in shares)	887,880
Stock-based compensation		193			193
Net loss for the year			(7,044)		(7,044)
Ending Balance at Dec. 31, 2020	$ 1	48,453	(48,551)	(856)	(953)
Ending Balance (in shares) at Dec. 31, 2020	111,429,532
Other comprehensive loss (income)				(515)	(515)
Issuance of shares to atai Life Sciences (net of transaction costs of $297)		8,398			8,398
Issuance of shares to atai Life Sciences (net of transaction costs of $297) (in shares)	37,300,000
Issuance of warrants to atai Life Sciences (net of transaction costs of $125)		3,526			3,526
Agents' warrants issued		164			164
Conversion of convertible notes		632			632
Conversion of convertible notes (in shares)	1,985,847
Conversion of convertible debentures		1,498			1,498
Conversion of convertible debentures (in shares)	3,852,000
Interest paid by issuance of common shares		1			1
Interest paid by issuance of common shares (in shares)	3,910
Stock-based compensation		107			107
Beneficial conversion feature, net of a deferred income tax liability of $86		325			325
Net loss for the year			(9,312)		(9,312)
Ending Balance at Dec. 31, 2021	$ 1	$ 63,104	$ (57,863)	$ (1,371)	$ 3,871
Ending Balance (in shares) at Dec. 31, 2021	154,571,289